Biliary Tract Cancer Clinical Trials

89 recruitingLast updated: June 17, 2026

There are 89 actively recruiting biliary tract cancer clinical trials across 41 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Biliary Tract Cancer Trials at a Glance

89 actively recruiting trials for biliary tract cancer are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Phase 2 with 47 trials, with the heaviest enrollment activity in Houston, Boston, and New York. Lead sponsors running biliary tract cancer studies include AstraZeneca, CHA University, and Suzhou Suncadia Biopharmaceuticals Co., Ltd..

Browse biliary tract cancer trials by phase

Treatments under study

About Biliary Tract Cancer Clinical Trials

Looking for clinical trials for Biliary Tract Cancer? There are currently 65 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Biliary Tract Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Biliary Tract Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 89 trials

Recruiting
Phase 1Phase 2

Study for AZD4360 in Participants With Advanced Solid Tumours

Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca117 enrolled18 locationsNCT06921928
Recruiting
Phase 3

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Biliary Tract Cancer
AstraZeneca620 enrolled270 locationsNCT06467357
Recruiting
Phase 3

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer (BTC)
InnoPharmax Inc.195 enrolled2 locationsNCT06622057
Recruiting
Phase 1Phase 2

Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

Biliary Tract CancerCholangiocarcinomaExtrahepatic Cholangiocarcinoma+2 more
Beijing Biotech30 enrolled1 locationNCT07641036
Recruiting
Phase 1Phase 2

Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer

Biliary Tract Cancer
West China Hospital20 enrolled1 locationNCT07636798
Recruiting
Phase 1

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Advanced Solid TumorsEwing SarcomaHepatocellular Carcinoma (HCC)+1 more
SEED Therapeutics, Inc.171 enrolled6 locationsNCT07197554
Recruiting
Early Phase 1

CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors

Biliary Tract CancerColorectal CarcinomaGastric Cancer, Metastatic+2 more
Zhejiang University36 enrolled1 locationNCT06937567
Recruiting
Phase 2

Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Biliary Tract Cancer
UNICANCER72 enrolled41 locationsNCT06529718
Recruiting
Phase 1Phase 2

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Lung CancersUrothelial CancerLocally Advanced+5 more
Avenzo Therapeutics, Inc.480 enrolled18 locationsNCT07038343
Recruiting
Phase 3

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

Biliary Tract Cancer (BTC)Advanced Biliary Tract Cancer
J-Pharma Co., Ltd.480 enrolled23 locationsNCT07265674
Recruiting
Phase 3

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Biliary Tract Cancer
Jazz Pharmaceuticals286 enrolled185 locationsNCT06282575
Recruiting
Phase 1

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins25 enrolled1 locationNCT06564623
Recruiting
Not Applicable

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Biliary Tract Cancer (BTC)
Peking University40 enrolled2 locationsNCT07466238
Recruiting
Phase 1Phase 2

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Breast CancerEsophageal CancerPancreatic Cancer+13 more
ModeX Therapeutics, An OPKO Health Company285 enrolled6 locationsNCT06239194
Recruiting
Phase 2

Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer

Biliary Tract Cancer
Air Force Military Medical University, China124 enrolled1 locationNCT07569679
Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Biliary Tract CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
SystImmune Inc.160 enrolled17 locationsNCT07021066
Recruiting

In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers

Pancreatic CancerCholangiocarcinomaPancreatic Cyst+4 more
University of Nottingham160 enrolled1 locationNCT07206355
Recruiting
Phase 2

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Biliary Tract CancerHepatocellular Carcinoma
AstraZeneca294 enrolled60 locationsNCT05775159
Recruiting
Phase 1Phase 2

HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours

Biliary Tract CancerMelanoma
Hangzhou Hanx Biopharmaceuticals, Ltd.124 enrolled1 locationNCT06708663
Recruiting
Phase 2

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University40 enrolled1 locationNCT07530445